Exemption from Bioequivalence Studies Adopted as New Topic at ICH Meeting in Lisbon; Could Affect Generics as Well

“Biowaivers” that would allow drug makers to skip conducting bioequivalence studies of oral agents if certain conditions are met was adopted as a new topic (M9) at a meeting of the International Council for Harmonization of Technical Requirements for Registration...read more